Careers  |  Sign In  |  Register  |   Twitter

Novartis Heart Failure Drug Has High Expectations

A clinical trial of Novartis‘ new heart failure drug, LCZ696 was stopped due to “overwhelmingly positive” results, Reuters article reports. Patients who struggle with chronic heart failure may find a newfound hope in the LCZ696 drug, as cardiologists found that the average expected relative risk reduction would be around 23 percent, measured by heart failure hospitalizations and mortality. If successful, Novartis expects that the new drug could see peak between $2 billion and $5 billion, with potential for even more.

Read the article published by Reuters.